Modular Medical, Inc.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- James E. Besser
- Full Time Employees
- 51
- Sector
- Healthcare
- Industry
- Medical - Devices
- Address
- 10740 Thornmint Road San Diego CA United States of America 92127
- IPO Date
- Feb 10, 2022
- CIK
- 0001074871
- Website
- modularmedical.com
- Similar Companies
- Business
- Modular Medical, Inc. (NASDAQ:MODD) develops and commercializes innovative insulin delivery systems for diabetes management, targeting type 1 and type 2 patients transitioning from multiple daily injections with simplified, affordable patch pump technology. The company offers MODD1, a two-part disposable patch pump featuring micro-pumping mechanics, user-friendly interfaces, data sharing capabilities for healthcare providers, and proprietary electronic controls; it also advances Pivot, a next-generation tubeless insulin pump undergoing clinical feasibility studies, Institutional Review Board-approved testing with sterile saline simulations, and preparations for FDA submission in October 2025 alongside CE mark pursuits for international markets. Founded in 1998 by Paul DiPerna, who previously led Tandem Diabetes Care, Modular Medical maintains headquarters at 10740 Thornmint Road, San Diego, California, operates from Nevada incorporation, employs 54 staff, and partners with Phillips-Medisize for scalable manufacturing while holding multiple U.S. and foreign patents on its technologies. Recent developments include a $12 million private placement in March 2025 to enhance MODD1 supply chain and margins while funding Pivot development; $1.3 million in insider purchases by CEO James Besser and affiliates at $1.92 per share; a $4.4 million warrant exercise in September 2025 yielding new five-year warrants at $0.84 exercise price; completion of a MODD1 clinical study with nine type 1 clinicians for Pivot refinements; and ongoing efforts toward mass-market adoption in the $3 billion diabetes device sector.
Modular Medical and IMO Health Launch Strategic Pilot to Enable Real Time Insulin Pump Patient Identification Into Electronic Health Records
Modular Medical Receives Research Demonstrating Positive Payor Reception of Pivot Tubeless Patch Pump
Modular Medical Announces Completion of Research Initiative Indicating Strong Interest in Simpler Insulin Delivery
Modular Medical Announces FDA Submission of Pivot Tubeless Insulin Patch Pump Enhancements
Modular Medical Delivers Insulin to First Patients on Pivot Tubeless Insulin Patch Pump
Modular Medical Announces Shipment of Pivot Tubeless Patch Pumps
Modular Medical Announces Commercial Availability of Pivot Tubeless Insulin Patch Pump Ahead of Commercial Expansion
Modular Medical Launches New Website for Pivot Tubeless Insulin Patch Pump
Registration Is Now Open For Tribe Public's CEO Presentation and Q&A Webinar Event Titled "From FDA Wins to Scaling Manufacturing - What Investors Should Watch." Featuring Modular Medical CEO - Friday, May 1, 2026
Modular Medical Announces Pricing of $3.4 Million Registered Direct Offering of Common Stock
Modular Medical Regains Compliance with Nasdaq Minimum Bid Price Requirement
Modular Medical Receives FDA 510(k) Clearance for Pivot Tubeless Insulin Patch Pump
Financial Comparison: Modular Medical (NASDAQ:MODD) and EssilorLuxottica (OTCMKTS:ESLOY)
Modular Medical Announces 1-for-30 Reverse Stock Split
Modular Medical Announces $12.0 Million Public Offering Priced at a Premium to Market
Modular Medical Achieves Key Manufacturing Milestone for Pivot Tubeless Insulin Patch Pump
Modular Medical Receives 180-Day Extension to Regain Compliance with Nasdaq Minimum Bid Price Rule
Modular Medical Announces Pricing of $4.68 Million Public Offering
Modular Medical Announces Proposed Public Offering
Modular Medical Receives IRB Approval to Deliver Insulin Using Pivot Patch Pump